Patients with AML and MDS with TP53 aberrations usually have a dismal prognosis even when treated with intensive regimens including allogeneic hematopoietic stem cell transplantation (HSCT) [17, 18]. The gene discussed is TP53; the disease is myelodysplastic syndrome.